Literature DB >> 21691915

Multinomial logistic functions in markov chain models of sleep architecture: internal and external validation and covariate analysis.

Roberto Bizzotto1, Stefano Zamuner, Enrica Mezzalana, Giuseppe De Nicolao, Roberto Gomeni, Andrew C Hooker, Mats O Karlsson.   

Abstract

Mixed-effect Markov chain models have been recently proposed to characterize the time course of transition probabilities between sleep stages in insomniac patients. The most recent one, based on multinomial logistic functions, was used as a base to develop a final model combining the strengths of the existing ones. This final model was validated on placebo data applying also new diagnostic methods and then used for the inclusion of potential age, gender, and BMI effects. Internal validation was performed through simplified posterior predictive check (sPPC), visual predictive check (VPC) for categorical data, and new visual methods based on stochastic simulation and estimation and called visual estimation check (VEC). External validation mainly relied on the evaluation of the objective function value and sPPC. Covariate effects were identified through stepwise covariate modeling within NONMEM VI. New model features were introduced in the model, providing significant sPPC improvements. Outcomes from VPC, VEC, and external validation were generally very good. Age, gender, and BMI were found to be statistically significant covariates, but their inclusion did not improve substantially the model's predictive performance. In summary, an improved model for sleep internal architecture has been developed and suitably validated in insomniac patients treated with placebo. Thereafter, covariate effects have been included into the final model.

Entities:  

Mesh:

Year:  2011        PMID: 21691915      PMCID: PMC3160167          DOI: 10.1208/s12248-011-9287-4

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  17 in total

1.  Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men.

Authors:  E Van Cauter; R Leproult; L Plat
Journal:  JAMA       Date:  2000-08-16       Impact factor: 56.272

2.  Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard.

Authors:  T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda
Journal:  Psychiatry Clin Neurosci       Date:  2001-06       Impact factor: 5.188

3.  Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model.

Authors:  Vincent Duval; Mats O Karlsson
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

4.  Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED.

Authors:  Siv Jönsson; Maria C Kjellsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-08       Impact factor: 2.745

5.  Insomnia: Prevalence, Impact, Pathogenesis, Differential Diagnosis, and Evaluation.

Authors:  Evelyn Mai; Daniel J Buysse
Journal:  Sleep Med Clin       Date:  2008

6.  Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients.

Authors:  Roberto Bizzotto; Stefano Zamuner; Giuseppe De Nicolao; Mats O Karlsson; Roberto Gomeni
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-01-06       Impact factor: 2.745

7.  Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Authors:  Radojka M Savic; Mats O Karlsson
Journal:  AAPS J       Date:  2009-08-01       Impact factor: 4.009

8.  Modeling sleep data for a new drug in development using markov mixed-effects models.

Authors:  Maria C Kjellsson; Daniele Ouellet; Brian Corrigan; Mats O Karlsson
Journal:  Pharm Res       Date:  2011-06-17       Impact factor: 4.200

9.  A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep.

Authors:  M O Karlsson; R C Schoemaker; B Kemp; A F Cohen; J M van Gerven; B Tuk; C C Peck; M Danhof
Journal:  Clin Pharmacol Ther       Date:  2000-08       Impact factor: 6.875

10.  The effects of age, sex, ethnicity, and sleep-disordered breathing on sleep architecture.

Authors:  Susan Redline; H Lester Kirchner; Stuart F Quan; Daniel J Gottlieb; Vishesh Kapur; Anne Newman
Journal:  Arch Intern Med       Date:  2004-02-23
View more
  5 in total

1.  A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.

Authors:  Sherwin K B Sy; Jules Heuberger; Sireen Shilbayeh; Daniela J Conrado; Hartmut Derendorf
Journal:  AAPS J       Date:  2013-08-30       Impact factor: 4.009

2.  A hidden Markov model to assess drug-induced sleep fragmentation in the telemetered rat.

Authors:  C Diack; O Ackaert; B A Ploeger; P H van der Graaf; R Gurrell; M Ivarsson; D Fairman
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-09-10       Impact factor: 2.745

3.  Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model.

Authors:  C Steven Ernest; Joakim Nyberg; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-12       Impact factor: 2.745

4.  Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations.

Authors:  Nikolaos Tsamandouras; Thierry Wendling; Amin Rostami-Hodjegan; Aleksandra Galetin; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-05-26       Impact factor: 2.745

5.  Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling.

Authors:  Patricia Martin-Romano; Belén P Solans; David Cano; Jose Carlos Subtil; Ana Chopitea; Leire Arbea; Maria Dolores Lozano; Eduardo Castanon; Iosune Baraibar; Diego Salas; Jose Luis Hernandez-Lizoain; Iñaki F Trocóniz; Javier Rodriguez
Journal:  PLoS One       Date:  2019-05-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.